贝利尤单抗治疗系统性红斑狼疮:早期病程与低基线损伤预测应答
该多中心回顾性研究纳入意大利24个中心466例接受静脉贝利尤单抗的活动性SLE患者,中位随访18个月。结果显示,基线SLEDAI-2K≥10、病程≤2年及基线SDI为0与较好应答相关;随访中达缓解或低疾病活动时间比例较高者损伤累积更少。
要点
- 基线SLEDAI-2K≥10与6、12、24、36个月SRI-4应答独立相关。
- 病程≤2年及基线SDI为0是早期治疗应答的预测因素。
- 缓解≥25%或低疾病活动≥50%随访期的患者损伤累积显著更少。
核心结论
- 在活动性SLE且基线损伤低的患者中,疾病早期使用贝利尤单抗可能获得更有利的真实世界结局。
研究设计与样本
- 多中心回顾性队列研究,纳入意大利24个中心466例接受静脉贝利尤单抗的活动性SLE患者,中位随访18个月(范围1-60个月)。
- 采用SRI-4评估应答,SDI每年评分损伤,多因素logistic回归分析预测因素并以OR及95%CI表达。
主要发现
- SRI-4应答率在6、12、24、36、48个月分别为49.2%、61.3%、69.7%、69.6%、66.7%。
- 6个月应答预测因素包括基线SLEDAI-2K≥10(OR 3.14 [95%CI 2.033-4.860])和病程≤2年(OR 1.94 [95%CI 1.078-3.473)。
- 12个月应答预测因素包括基线SLEDAI-2K≥10(OR 3.48 [95%CI 2.004-6.025])和SDI为0(OR 1.74 [95%CI 1.036-2.923])。
- 24个月应答预测因素包括基线SLEDAI-2K≥10(OR 4.25 [95%CI 2.018-8.940])和病程≤2年(OR 3.79 [95%CI 1.039-13.52])。
- 36个月应答预测因素包括基线SLEDAI-2K≥10(OR 14.59 [95%CI 3.54-59.79]),当前吸烟者为负相关(OR 0.19 [95%CI 0.039-0.69])。
关键数值与推荐
- 随访中缓解≥25%者占44.3%、低疾病活动≥50%者占66.1%,其损伤累积显著更少(P=0.046和P=0.007)。
- 基线SDI为0是达低疾病活动≥50%随访期及缓解≥25%随访期的独立预测因素。
- 贝利尤单抗启用前 flare 次数与因无效停药频率呈负相关(P=0.009)。
临床怎么用
- 对活动性SLE且基线损伤低、病程短的患者,可考虑尽早使用贝利尤单抗以争取更佳应答。
- 基线SLEDAI-2K≥10提示较高应答概率,可作为治疗决策参考。
- 当前吸烟与36个月应答负相关,治疗前应重视戒烟干预。
局限性
- 为回顾性多中心队列研究,可能存在选择偏倚与混杂。
- 随访时间不等(1-60个月),部分时间点事件数有限使OR置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate predictors of response, remission, low disease activity, damage, and drug discontinuation in patients with systemic lupus erythematosus (SLE) who were treated with belimumab. METHODS: In this retrospective study of a multicenter cohort of SLE patients who received intravenous belimumab, the proportion of patients who achieved remission, low disease activity, and treatment response according to the SLE Responder Index 4 (SRI-4) was determined, and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) was used to score disease damage yearly over the follow-up. Predictors of outcomes were analyzed by multivariate logistic regression with the results expressed as odds ratios (ORs) and 95% confidence intervals (95% CIs). RESULTS: The study included 466 patients with active SLE from 24 Italian centers, with a median follow-up period of 18 months (range 1-60 months). An SRI-4 response was achieved by 49.2%, 61.3%, 69.7%, 69.6%, and 66.7% of patients at 6, 12, 24, 36, and 48 months, respectively. Baseline predictors of response at 6 months included a score of ≥10 on the SLE Disease Activity Index 2000 (SLEDAI-2K) (OR 3.14 [95% CI 2.033-4.860]) and a disease duration of ≤2 years (OR 1.94 [95% CI 1.078-3.473). Baseline predictors of response at 12 months included a score of ≥10 on the SLEDAI-2K (OR 3.48 [95% CI 2.004-6.025]) and an SDI score of 0 (OR 1.74 [95% CI 1.036-2.923]). Baseline predictors of response at 24 months included a score of ≥10 on the SLEDAI-2K (OR 4.25 [95% CI 2.018-8.940]) and a disease duration of ≤2 years (OR 3.79 [95% CI 1.039-13.52]). Baseline predictors of response at 36 months included a score of ≥10 on the SLEDAI-2K (OR 14.59 [95% CI 3.54-59.79) and baseline status of current smoker (OR 0.19 [95% CI 0.039-0.69]). Patients who were in remission for ≥25% of the follow-up period (44.3%) or who had low disease activity for ≥50% of the follow-up period (66.1%) accrued significantly less damage (P = 0.046 and P = 0.007). A baseline SDI score of 0 was an independent predictor of achieving low disease activity in ≥50% of the follow-up period and remission in ≥25% of the follow-up period. Our findings suggest that the lower the baseline damage, the greater the probability of achieving remission over the course of ≥25% of the follow-up. Further, there was a negative association between the number of flares reported prior to belimumab initiation and the frequency of belimumab discontinuation due to inefficacy (P = 0.009). CONCLUSION: In patients with active SLE and low damage at baseline, treatment with belimumab early in the disease may lead to favorable outcomes in a real-life setting.
引用
- Gatto M, Saccon F, Zen M, et al. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. Arthritis Rheumatol. 2020. PMID: 32275125. doi:10.1002/art.41253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。